We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Entelos Regs | LSE:ENTL | London | Ordinary Share | COM SHS USD0.001 (REG S) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
TIDMENTLEntelos, Inc.
Management Changes
Entelos, Inc. ("Entelos" or the "Company") announces changes to its senior management team.
Jim Neal is appointed as Acting President and Acting Chief Executive Officer. In addition, the Company announces that it is in advanced negotiations with candidates for the position of Acting Chief Financial Officer. The Company also announced the appointment of Julie Thomas Goggin as its General Counsel and Corporate Secretary.
Jim Neal was most recently Entelos' Chief Business Officer, and prior to that was the Chief Executive Officer of Iconix Biosciences, Inc., a company acquired by Entelos in 2007. Julie Thomas Goggin was most recently the Company's General Counsel. In addition, Entelos announces the departure of James Karis, the Company's former Chief Executive Officer and Alan Blazei, the Company's former Chief Financial Officer and Company Secretary.
Enquiries
Entelos, Inc. Jon Saxe, Chairman Tel: +1 650 572 5400 KBC Peel Hunt, Ltd (Nominated Advisor and Broker) Capel Irwin/David Anderson Tel: +44 (0) 20 4718 8900 Buchanan Communications Lisa Baderoon/Mary-Jane Johnson Tel: +44 (0)20 7466 5000About Entelos
Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical, health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.
1 Year Entelos Regs Chart |
1 Month Entelos Regs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
